Fang Liz Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fang Liz Zhou has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Paulos Berhanu
Department of US Medical Affairs, Sanofi, Bridgewater, New Jersey
5 shared publicationsRonald Preblick
Department of Health Economics and Value Access, Sanofi, Bridgewater, New Jersey
5 shared publications- Lawrence Blonde
Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute, Department of Endocrinology Ochsner Medical Center New Orleans Louisiana USA
4 shared publications Rishab A. Gupta
Department of Applied Intelligence, Accenture, Florham Park, New Jersey
4 shared publicationsTimothy S. Bailey
AMCR Institute, Escondido, California
4 shared publications- Jochen Seufert
Klinik für Innere Medizin II, Abteilung Endokrinologie und Diabetologie, Universitätsklinikum Freiburg, Freiburg, Germany
3 shared publications
Latest Publications
- Open Access
- 4 October 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 104, 106785
Identification of risk profiles for liver injury in adults with multiple sclerosis using artificial intelligence method
- 4 October 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 104, 106785
Open AccessIdentification of risk profiles for liver injury in adults with multiple sclerosis using artificial intelligence method
- Open Access
- 28 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 4951
A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study
Introduction: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy. Some patients experience prolonged remission after aggressive chemotherapy, but the only current therapy with proven curative potential is allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, not all CMML patients benefit from allo-HSCT, and many experience relapse. Relapse is the leading cause of treatment failure for CMML treated with allo-HSCT, and treatment options for patients relapsing after allo-HSCT are limited. This study conducted a nationwide multicenter real-world study to identify risk factors and develop a novel prediction model for early recurrence in CMML patient posttransplantation. Clinicians can improve the survival of CMML patients with a high risk of early recurrence by intervening as early as possible. Methods: Patients ≥18 years old with CMML treated with allo-HSCT for the first time between 2005 and 2022 were included in this nationwide, multicenter, real-world study. Twenty-seven medical centers participated in this analysis, including the derivation cohort from 26 centers and the validation cohort from another center. Information collected included demographic and clinical characteristics, previous treatments and responses, and allo-HSCT treatment details. We first calculated the univariable association of each variable with 1-year relapse in the derivation cohort. Second, the variables with p values less than 0.1 in the univariate analysis were further included as candidate predictors in the multivariate analysis using a backward stepwise logistic regression model. The variables that remained in the final model based on the outcomes of the multivariate analysis in the derivation cohort were identified as independent prognostic factors. A scoring system to predict early recurrence after allo-HSCT was also established, and scores were assigned to the prognostic factors based on the regression coefficient. Results: Using multivariable logistic regression methods with stepwise variable selection, two highly significant independent prognostic factors for the early recurrence of CMML posttransplantation were identified: bone marrow blast cell count at diagnosis (p=0.026; odds ratio [OR], 1.149; 95% confidence interval [CI], 1.02-1.30), and leukocyte count pretransplantation (p=0.005; odds ratio [OR], 1.212; 95% confidence interval [CI], 1.06-1.39). A risk grading model was constructed according to the regression coefficients. Bone marrow blast cell count 0-5% is 0 point, 5%-10% is 1 point; 10-20% is 2 points, and >20% is 3 points. Leukocyte count 0-10×10 9/L is 0 point, 10-20×10 9/L is 2 points, and >20 ×10 9/L is 4 points. The points scored for each of these two factors were added to yield the overall risk score, which ranged from zero to seven. Patients were stratified into a low-risk group (0-1 point), a intermediate-risk group (2-3 points) and a high-risk group (4-7 points). The validated internal c-statistic was 0.790 (95% CI, 0.657-0.923), and the external c-statistic was 0.710 (95% CI, 0.580-0.840). The early recurrence rates of the derivation cohort in the low-risk, intermediate-risk, and high-risk groups were 5.9%, 17.9% and 31.8% (pConclusion: CMML patients who relapse after allo-HSCT have a poor prognosis. An integrated prediction model based on clinical biomarkers was developed and externally validated, and this is the first straightforward scoring model that incorporates clinical and laboratory risk factors to evaluate the early recurrence of CMML patients after receiving allo-HSCT. This model can be effectively utilized to help improve the survival and prognosis of CMML patients by accelerating the early identification of patients at a high risk of relapse and contributing to the appropriate implementation of urgent medical support. No relevant conflicts of interest to declare.
- 28 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 4951
Open AccessA Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study
Introduction: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy. Some patients experience prolonged remission after aggressive chemotherapy, but the only current therapy with proven curative potential is allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, not all CMML patients benefit from allo-HSCT, and many experience relapse. Relapse is the leading cause of treatment failure for CMML treated with allo-HSCT, and treatment options for patients relapsing after allo-HSCT are limited. This study conducted a nationwide multicenter real-world study to identify risk factors and develop a novel prediction model for early recurrence in CMML patient posttransplantation. Clinicians can improve the survival of CMML patients with a high risk of early recurrence by intervening as early as possible. Methods: Patients ≥18 years old with CMML treated with allo-HSCT for the first time between 2005 and 2022 were included in this nationwide, multicenter, real-world study. Twenty-seven medical centers participated in this analysis, including the derivation cohort from 26 centers and the validation cohort from another center. Information collected included demographic and clinical characteristics, previous treatments and responses, and allo-HSCT treatment details. We first calculated the univariable association of each variable with 1-year relapse in the derivation cohort. Second, the variables with p values less than 0.1 in the univariate analysis were further included as candidate predictors in the multivariate analysis using a backward stepwise logistic regression model. The variables that remained in the final model based on the outcomes of the multivariate analysis in the derivation cohort were identified as independent prognostic factors. A scoring system to predict early recurrence after allo-HSCT was also established, and scores were assigned to the prognostic factors based on the regression coefficient. Results: Using multivariable logistic regression methods with stepwise variable selection, two highly significant independent prognostic factors for the early recurrence of CMML posttransplantation were identified: bone marrow blast cell count at diagnosis (p=0.026; odds ratio [OR], 1.149; 95% confidence interval [CI], 1.02-1.30), and leukocyte count pretransplantation (p=0.005; odds ratio [OR], 1.212; 95% confidence interval [CI], 1.06-1.39). A risk grading model was constructed according to the regression coefficients. Bone marrow blast cell count 0-5% is 0 point, 5%-10% is 1 point; 10-20% is 2 points, and >20% is 3 points. Leukocyte count 0-10×10 9/L is 0 point, 10-20×10 9/L is 2 points, and >20 ×10 9/L is 4 points. The points scored for each of these two factors were added to yield the overall risk score, which ranged from zero to seven. Patients were stratified into a low-risk group (0-1 point), a intermediate-risk group (2-3 points) and a high-risk group (4-7 points). The validated internal c-statistic was 0.790 (95% CI, 0.657-0.923), and the external c-statistic was 0.710 (95% CI, 0.580-0.840). The early recurrence rates of the derivation cohort in the low-risk, intermediate-risk, and high-risk groups were 5.9%, 17.9% and 31.8% (pConclusion: CMML patients who relapse after allo-HSCT have a poor prognosis. An integrated prediction model based on clinical biomarkers was developed and externally validated, and this is the first straightforward scoring model that incorporates clinical and laboratory risk factors to evaluate the early recurrence of CMML patients after receiving allo-HSCT. This model can be effectively utilized to help improve the survival and prognosis of CMML patients by accelerating the early identification of patients at a high risk of relapse and contributing to the appropriate implementation of urgent medical support. No relevant conflicts of interest to declare.
- Open Access
- 25 September 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (12) , 3478-3489
Patient and physician perspectives and experiences of basal insulin titration in type 2 diabetes in the United States: Cross‐sectional surveys
Aim: Patient‐ and physician‐associated barriers impact the effectiveness of basal insulin (BI) titration in the management of type 2 diabetes (T2D). We evaluated the experiences of patients with T2D and physicians with BI titration education. Materials and Methods: In this observational, cross‐sectional study, patients with T2D and physicians treating patients with T2D were identified by claims in the Optum Research Database and were invited to complete a survey. Eligible patients had 12 months of continuous health‐plan enrolment with medical and pharmacy benefits during the baseline period, and recent initiation of BI therapy. Eligible physicians had initiated BI for ≥1 eligible patient with T2D during the past 6 months. Results: In total, 416 patients and 386 physicians completed the survey. Ninety per cent of physicians reported treating ≥50 patients with T2D; 66% treated ≥25% of patients with BI. Whereas 74% of patients reported that BI titration was explained to them by a physician, 96% of physicians reported doing so. Furthermore, 20% of patients stated they were offered educational materials whereas 56% of physicians reported having provided materials. Physicians had higher expectations of glycaemic target achievement than were seen in the patient survey; their main concern was the patients' ability to titrate accurately (79%). Conclusions: There is a marked difference in patients' and physicians' experiences of BI titration education. Novel tools and strategies are required to enable effective BI titration, with more educational resources at the outset, and ongoing access to tools that provide clear, simple direction for self‐titration with less reliance on physicians/health care providers.
- 25 September 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (12) , 3478-3489
Open AccessPatient and physician perspectives and experiences of basal insulin titration in type 2 diabetes in the United States: Cross‐sectional surveys
Aim: Patient‐ and physician‐associated barriers impact the effectiveness of basal insulin (BI) titration in the management of type 2 diabetes (T2D). We evaluated the experiences of patients with T2D and physicians with BI titration education. Materials and Methods: In this observational, cross‐sectional study, patients with T2D and physicians treating patients with T2D were identified by claims in the Optum Research Database and were invited to complete a survey. Eligible patients had 12 months of continuous health‐plan enrolment with medical and pharmacy benefits during the baseline period, and recent initiation of BI therapy. Eligible physicians had initiated BI for ≥1 eligible patient with T2D during the past 6 months. Results: In total, 416 patients and 386 physicians completed the survey. Ninety per cent of physicians reported treating ≥50 patients with T2D; 66% treated ≥25% of patients with BI. Whereas 74% of patients reported that BI titration was explained to them by a physician, 96% of physicians reported doing so. Furthermore, 20% of patients stated they were offered educational materials whereas 56% of physicians reported having provided materials. Physicians had higher expectations of glycaemic target achievement than were seen in the patient survey; their main concern was the patients' ability to titrate accurately (79%). Conclusions: There is a marked difference in patients' and physicians' experiences of BI titration education. Novel tools and strategies are required to enable effective BI titration, with more educational resources at the outset, and ongoing access to tools that provide clear, simple direction for self‐titration with less reliance on physicians/health care providers.
- Open Access
- 16 April 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (7) , 1823-1829
Identification of predictive factors of diabetic ketoacidosis in type 1 diabetes using a subgroup discovery algorithm
Aim: To identify predictive factors for diabetic ketoacidosis (DKA) by retrospective analysis of registry data and the use of a subgroup discovery algorithm. Materials and Methods: Data from adults and children with type 1 diabetes and more than two diabetes‐related visits were analysed from the Diabetes Prospective Follow‐up Registry. Q‐Finder, a supervised non‐parametric proprietary subgroup discovery algorithm, was used to identify subgroups with clinical characteristics associated with increased DKA risk. DKA was defined as pH less than 7.3 during a hospitalization event. Results: Data for 108 223 adults and children, of whom 5609 (5.2%) had DKA, were studied. Q‐Finder analysis identified 11 profiles associated with an increased risk of DKA: low body mass index standard deviation score; DKA at diagnosis; age 6‐10 years; age 11‐15 years; an HbA1c of 8.87% or higher (≥ 73 mmol/mol); no fast‐acting insulin intake; age younger than 15 years and not using a continuous glucose monitoring system; physician diagnosis of nephrotic kidney disease; severe hypoglycaemia; hypoglycaemic coma; and autoimmune thyroiditis. Risk of DKA increased with the number of risk profiles matching patients’ characteristics. Conclusions: Q‐Finder confirmed common risk profiles identified by conventional statistical methods and allowed the generation of new profiles that may help predict patients with type 1 diabetes who are at a greater risk of experiencing DKA.
- 16 April 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (7) , 1823-1829
Open AccessIdentification of predictive factors of diabetic ketoacidosis in type 1 diabetes using a subgroup discovery algorithm
Aim: To identify predictive factors for diabetic ketoacidosis (DKA) by retrospective analysis of registry data and the use of a subgroup discovery algorithm. Materials and Methods: Data from adults and children with type 1 diabetes and more than two diabetes‐related visits were analysed from the Diabetes Prospective Follow‐up Registry. Q‐Finder, a supervised non‐parametric proprietary subgroup discovery algorithm, was used to identify subgroups with clinical characteristics associated with increased DKA risk. DKA was defined as pH less than 7.3 during a hospitalization event. Results: Data for 108 223 adults and children, of whom 5609 (5.2%) had DKA, were studied. Q‐Finder analysis identified 11 profiles associated with an increased risk of DKA: low body mass index standard deviation score; DKA at diagnosis; age 6‐10 years; age 11‐15 years; an HbA1c of 8.87% or higher (≥ 73 mmol/mol); no fast‐acting insulin intake; age younger than 15 years and not using a continuous glucose monitoring system; physician diagnosis of nephrotic kidney disease; severe hypoglycaemia; hypoglycaemic coma; and autoimmune thyroiditis. Risk of DKA increased with the number of risk profiles matching patients’ characteristics. Conclusions: Q‐Finder confirmed common risk profiles identified by conventional statistical methods and allowed the generation of new profiles that may help predict patients with type 1 diabetes who are at a greater risk of experiencing DKA.
- Open Access
- 31 January 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (5) , 1408-1412
Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross‐sectional survey
- 31 January 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (5) , 1408-1412
Open AccessPatient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross‐sectional survey
- Open Access
- 2 December 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (4) , 622-630
Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: A real‐world study of more than 30 000 patients in a US electronic health record database
Aims: To use electronic health record data from real‐world clinical practice to assess demographics, clinical characteristics and disease burden of adults with type 1 diabetes (T1D) in the United States. Materials and methods: Retrospective observational study of adults with T1D for ≥24 months at their first visit with a T1D diagnosis code (“index date”) between July 2014 and June 2016 in the Optum Humedica database. Demographic characteristics, acute complications (severe hypoglycaemia [SH], diabetic ketoacidosis [DKA]), microvascular complications, cardiovascular (CV) events and health care resource utilization during the 12 months before the index date (“baseline period”) were compared between patients with optimal versus suboptimal glycaemic control (glycated haemoglobin [HbA1c] 30 000 adults with T1D showed that individuals with suboptimal versus optimal glycaemic control differed significantly in terms of health care coverage, comorbidities, diabetes‐related complications, health care utilization and CV risk factors. However, suboptimal control was not associated with increased risk of CV outcomes.
- 2 December 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (4) , 622-630
Open AccessDifferences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: A real‐world study of more than 30 000 patients in a US electronic health record database
Aims: To use electronic health record data from real‐world clinical practice to assess demographics, clinical characteristics and disease burden of adults with type 1 diabetes (T1D) in the United States. Materials and methods: Retrospective observational study of adults with T1D for ≥24 months at their first visit with a T1D diagnosis code (“index date”) between July 2014 and June 2016 in the Optum Humedica database. Demographic characteristics, acute complications (severe hypoglycaemia [SH], diabetic ketoacidosis [DKA]), microvascular complications, cardiovascular (CV) events and health care resource utilization during the 12 months before the index date (“baseline period”) were compared between patients with optimal versus suboptimal glycaemic control (glycated haemoglobin [HbA1c] 30 000 adults with T1D showed that individuals with suboptimal versus optimal glycaemic control differed significantly in terms of health care coverage, comorbidities, diabetes‐related complications, health care utilization and CV risk factors. However, suboptimal control was not associated with increased risk of CV outcomes.
- Open Access
- 23 September 2019
- Published by American Diabetes Association in Diabetes Care
- Vol. 42 (12) , 2220-2227
Incidences of Severe Hypoglycemia and Diabetic Ketoacidosis and Prevalence of Microvascular Complications Stratified by Age and Glycemic Control in U.S. Adult Patients With Type 1 Diabetes: A Real-World Study
OBJECTIVE To assess the burden of disease for adults with type 1 diabetes in a U.S. electronic health record database by evaluating acute and microvascular complications stratified by age and glycemic control. RESEARCH DESIGN AND METHODS This is a retrospective observational study of adults with type 1 diabetes (1 July 2014–30 June 2016) classified using a validated algorithm, with disease duration ≥24 months and, during a 12-month baseline period, not pregnant and having one or more insulin prescriptions and one or more HbA1c measurements. Demographic characteristics, acute complications (severe hypoglycemia [SH], diabetic ketoacidosis [DKA]), and microvascular complications (neuropathy, nephropathy, retinopathy) were stratified by age (18–25, 26–49, 50–64, ≥65 years) and glycemic control (HbA1c 1c 1c values than younger patients (P < 0.001). Patients with poor glycemic control had the highest annual incidence of SH (4.2%, 4.0%, and 8.3%) and DKA (1.3%, 2.8%, and 15.8%) for HbA1c P < 0.001), and a higher prevalence of neuropathy and nephropathy (both P < 0.001). CONCLUSIONS For adults with type 1 diabetes, glycemic control appears worse than previously estimated. Rates of all complications increased with increasing HbA1c. Compared with HbA1c 1c ≥9% was associated with twofold and 12-fold higher incidences of SH and DKA, respectively. Younger adults had more pronounced higher risks of SH and DKA associated with poor glycemic control than older adults.
- 23 September 2019
- Published by American Diabetes Association in Diabetes Care
- Vol. 42 (12) , 2220-2227
Open AccessIncidences of Severe Hypoglycemia and Diabetic Ketoacidosis and Prevalence of Microvascular Complications Stratified by Age and Glycemic Control in U.S. Adult Patients With Type 1 Diabetes: A Real-World Study
OBJECTIVE To assess the burden of disease for adults with type 1 diabetes in a U.S. electronic health record database by evaluating acute and microvascular complications stratified by age and glycemic control. RESEARCH DESIGN AND METHODS This is a retrospective observational study of adults with type 1 diabetes (1 July 2014–30 June 2016) classified using a validated algorithm, with disease duration ≥24 months and, during a 12-month baseline period, not pregnant and having one or more insulin prescriptions and one or more HbA1c measurements. Demographic characteristics, acute complications (severe hypoglycemia [SH], diabetic ketoacidosis [DKA]), and microvascular complications (neuropathy, nephropathy, retinopathy) were stratified by age (18–25, 26–49, 50–64, ≥65 years) and glycemic control (HbA1c 1c 1c values than younger patients (P < 0.001). Patients with poor glycemic control had the highest annual incidence of SH (4.2%, 4.0%, and 8.3%) and DKA (1.3%, 2.8%, and 15.8%) for HbA1c P < 0.001), and a higher prevalence of neuropathy and nephropathy (both P < 0.001). CONCLUSIONS For adults with type 1 diabetes, glycemic control appears worse than previously estimated. Rates of all complications increased with increasing HbA1c. Compared with HbA1c 1c ≥9% was associated with twofold and 12-fold higher incidences of SH and DKA, respectively. Younger adults had more pronounced higher risks of SH and DKA associated with poor glycemic control than older adults.
- Open Access
- 2 July 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (11) , 2384-2393
Switching to insulin glargine 300 units/mL in real‐world older patients with type 2 diabetes (DELIVER 3)
Aim: To compare the second‐generation basal insulin glargine 300 units/mL (Gla‐300) and first‐generation basal insulins on glycaemic control and hypoglycaemia risk in older adults with type 2 diabetes (T2D). Materials and methods: DELIVER 3 was a retrospective observational cohort study of electronic medical records. A total of 1176 older adults (aged ≥ 65 years) with T2D and ≥1 HbA1c value during 6 month baseline and 3 to 6 month follow‐up who switched from basal insulin to Gla‐300 were propensity score‐matched to 1176 older adults who switched to a first‐generation basal insulin [insulin detemir (IDet) or insulin glargine 100 units/mL (Gla‐100)]. Outcomes were follow‐up HbA1c, achievement of HbA1c P = .021; fixed follow‐up: −0.48% ± 1.49% vs. −0.38% ± 1.59%; P = .114), while HbA1c goal attainment was similar in both cohorts. Gla‐300 was associated with less hypoglycaemia [event rate: adjusted rate ratio (aRR): 0.63, 95% CI: 0.53‐0.75; P < .001] and inpatient/emergency department‐associated hypoglycaemia (adjusted hazard ratio: 0.58, 95% CI: 0.37‐0.90; P = .016; aRR: 0.43, 95% CI: 0.31‐0.60; P < .001) by variable follow‐up. By fixed follow‐up, hypoglycaemia results significantly or numerically favoured Gla‐300. Conclusion: Among older adults with T2D, switching to Gla‐300 versus Gla‐100/IDet was associated with greater/similar improvements in glycaemic control, and generally less hypoglycaemia.
- 2 July 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (11) , 2384-2393
Open AccessSwitching to insulin glargine 300 units/mL in real‐world older patients with type 2 diabetes (DELIVER 3)
Aim: To compare the second‐generation basal insulin glargine 300 units/mL (Gla‐300) and first‐generation basal insulins on glycaemic control and hypoglycaemia risk in older adults with type 2 diabetes (T2D). Materials and methods: DELIVER 3 was a retrospective observational cohort study of electronic medical records. A total of 1176 older adults (aged ≥ 65 years) with T2D and ≥1 HbA1c value during 6 month baseline and 3 to 6 month follow‐up who switched from basal insulin to Gla‐300 were propensity score‐matched to 1176 older adults who switched to a first‐generation basal insulin [insulin detemir (IDet) or insulin glargine 100 units/mL (Gla‐100)]. Outcomes were follow‐up HbA1c, achievement of HbA1c P = .021; fixed follow‐up: −0.48% ± 1.49% vs. −0.38% ± 1.59%; P = .114), while HbA1c goal attainment was similar in both cohorts. Gla‐300 was associated with less hypoglycaemia [event rate: adjusted rate ratio (aRR): 0.63, 95% CI: 0.53‐0.75; P < .001] and inpatient/emergency department‐associated hypoglycaemia (adjusted hazard ratio: 0.58, 95% CI: 0.37‐0.90; P = .016; aRR: 0.43, 95% CI: 0.31‐0.60; P < .001) by variable follow‐up. By fixed follow‐up, hypoglycaemia results significantly or numerically favoured Gla‐300. Conclusion: Among older adults with T2D, switching to Gla‐300 versus Gla‐100/IDet was associated with greater/similar improvements in glycaemic control, and generally less hypoglycaemia.
- Open Access
- 14 June 2019
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 2 (3) , e00073
Hypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting
Introduction: Type 2 diabetes (T2D) is characterized by worsening pancreatic β‐cell function often requiring treatment escalation with oral antidiabetic drugs (OADs), glucagon‐like peptide‐1 and eventually insulin. Although there is much evidence available on the initiation of basal insulins, fewer studies have investigated the effects of switching from one basal insulin to another. This study aims to evaluate treatment persistence and hypoglycaemia in adult patients with T2D on prior basal insulin who were switched to insulin glargine 300 units/mL (Gla‐300) or other basal insulins in a real‐world setting.Materials and methods: This study is a retrospective cohort analysis of patient‐level data extracted from the Optum® Clinformatics™ database between 1 October 2014 and 30 June 2016. Adult patients (≥18 years) with T2D who were being treated with basal insulin during the 6‐month baseline period, who switched to either Gla‐300 or other basal insulins, were followed up for ≥3 months after switching. Outcomes included treatment persistence, and incidence and number of hypoglycaemic events.Results: Of the included patients, 1204 switched to Gla‐300 and 616 switched to other basal insulins. Adjusting for baseline confounders, patients who switched to Gla‐300 were 34% less likely to discontinue their basal insulin than patients who switched to other basal insulins (hazard ratio [HR] 0.66; 95% confidence interval [CI] 0.54‐0.81; P < 0.001). Patients who switched to Gla‐300 were less likely to experience hypoglycaemia at 3‐month follow‐up (odds ratio [OR] 0.56, 95% CI 0.32‐0.97; P = 0.039) and at 6‐month follow‐up (OR 0.58, 95% CI 0.38‐0.87; P = 0.009) compared with patients who switched to other basal insulins.Conclusions: Patients with T2D on prior basal insulin in a real‐world setting who switched to Gla‐300 were more persistent with their basal insulin and experienced less hypoglycaemia than patients who switched to other basal insulins.
- 14 June 2019
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 2 (3) , e00073
Open AccessHypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting
Introduction: Type 2 diabetes (T2D) is characterized by worsening pancreatic β‐cell function often requiring treatment escalation with oral antidiabetic drugs (OADs), glucagon‐like peptide‐1 and eventually insulin. Although there is much evidence available on the initiation of basal insulins, fewer studies have investigated the effects of switching from one basal insulin to another. This study aims to evaluate treatment persistence and hypoglycaemia in adult patients with T2D on prior basal insulin who were switched to insulin glargine 300 units/mL (Gla‐300) or other basal insulins in a real‐world setting.Materials and methods: This study is a retrospective cohort analysis of patient‐level data extracted from the Optum® Clinformatics™ database between 1 October 2014 and 30 June 2016. Adult patients (≥18 years) with T2D who were being treated with basal insulin during the 6‐month baseline period, who switched to either Gla‐300 or other basal insulins, were followed up for ≥3 months after switching. Outcomes included treatment persistence, and incidence and number of hypoglycaemic events.Results: Of the included patients, 1204 switched to Gla‐300 and 616 switched to other basal insulins. Adjusting for baseline confounders, patients who switched to Gla‐300 were 34% less likely to discontinue their basal insulin than patients who switched to other basal insulins (hazard ratio [HR] 0.66; 95% confidence interval [CI] 0.54‐0.81; P < 0.001). Patients who switched to Gla‐300 were less likely to experience hypoglycaemia at 3‐month follow‐up (odds ratio [OR] 0.56, 95% CI 0.32‐0.97; P = 0.039) and at 6‐month follow‐up (OR 0.58, 95% CI 0.38‐0.87; P = 0.009) compared with patients who switched to other basal insulins.Conclusions: Patients with T2D on prior basal insulin in a real‐world setting who switched to Gla‐300 were more persistent with their basal insulin and experienced less hypoglycaemia than patients who switched to other basal insulins.
- Open Access
- 7 June 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 25 (21) , 2650-2664
Novel risk scoring system for prediction of pancreatic fistula after pancreaticoduodenectomy
Novel risk scoring system for prediction of pancreatic fistula after pancreaticoduodenectomy
- 7 June 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 25 (21) , 2650-2664
Open AccessNovel risk scoring system for prediction of pancreatic fistula after pancreaticoduodenectomy
Novel risk scoring system for prediction of pancreatic fistula after pancreaticoduodenectomy